Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

Powderly, JohnCote, GregoryFlaherty, KeithSzmulewitz, Russell ZRibas, AntoniWeber, JeffreyLoo, DerykBaughman, JanChen, FrancineMoore, PaulBonvini, EzioVasselli, JamesWigginton, JonCohen, RogerBurris, HowardChmielowski, Bartosz2015-12-042015Powderly, J., G. Cote, K. Flaherty, R. Z. Szmulewitz, A. Ribas, J. Weber, D. Loo, et al. 2015. “Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3.” Journal for Immunotherapy of Cancer 3 (Suppl 2): O8. doi:10.1186/2051-1426-3-S2-O8. http://dx.doi.org/10.1186/2051-1426-3-S2-O8.2051-1426http://nrs.harvard.edu/urn-3:HUL.InstRepos:23845253en-USInterim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3Journal Article2015-12-0410.1186/2051-1426-3-S2-O8